/R E P E A T -- AMP Appoints National Sales Director and Launches Nationwide Marketing Sales Campaign for Branded Medical Cannabis Products in Germany/

AMP Alternative Medical Products Inc. (Frankfurt: C4TA) (ISIN: CA0318961038) (CSE: XCX), a pharmaceutical supplier of medical cannabis to German pharmacies, announces the appointment of Mr. Robert Schenk as National Sales Director and the launch of AMP's nationwide Marketing Sales Campaign for branded medical cannabis products.

Mr. Schenk, who will oversee the development and execution of AMP's sales and marketing strategies and lead our nationwide sales team, officially joins AMP today. Mr. Schenk brings over 20 years of experience in the pharmaceutical industry to AMP and was most recently, Regional Manager of Canopy Growth Germany GmbH, a subsidiary of Canopy Growth Corporation (Nasdaq: CGC ), where he established, built and lead Canopy's nationwide sales team in Germany.

AMP also launched its marketing sales campaign for AMP's line of branded medical cannabis products, which includes cannabis flower products: Aphria Strong 9, Bedrocan and Bediol Cannabis Floss, as well as extracts: Little Green Pharma Classic 20:5 and Classic 10:10. AMP will be launching its cannabis flower product AMP Classic 18/1 Primary in May 2021 supplied by Schroll Medical and additional AMP branded flower and extract products from Canada as well as Australia during the second half of the year. German doctors and pharmacists can find further information about AMP's medical cannabis products at www.amp-eu.com/doccheck-login/ .

AMP's nationwide sales team includes highly capable and accomplished pharmaceutical sales representatives in Stade, Cologne , Nordhausen and Speyer who are selling Aphria and AMP's catalogue of medical cannabis products to over 13,000 pharmacies under AMP's co-promotion agreement with CC Pharma , a national pharmaceutical distributor and a wholly-owned subsidiary of Aphria Inc. (Nasdaq: APHA ).

AMP's Sales Team Group Picture (CNW Group/AMP Alternative Medical Products)

Photo: AMP's management and sales team. You can view this photo at: https://twitter.com/AMP_Cannabis/status/1379631320956071936

AMP and CC Pharma are jointly training their sales teams on how to advance knowledge among doctors and best practices fulfilling medical cannabis prescriptions and how medical cannabis can help in patient therapy and ensuring that pharmacies nationwide have access to AMP's selection of medical cannabis products.

To advance the benefits of medical cannabis therapy knowledge, AMP and CC Pharma are holding education seminars across Germany for doctors and pharmacists.

AMP also launched its new website ( www.amp-eu.com ) which provides information about medical cannabis and a secure portal for doctors and pharmacists for information about our products and how to contact our sales team.

Dr. Stefan Feuerstein , President and Director of AMP, commented, "Our strategy is to focus on servicing our customers and commit to advance medical cannabis therapy for the patient. AMP and CC Pharma are committed to this strategy and are advancing education about the health benefits of cannabis and best practices for patient therapy in the medical community through our joint education seminars for doctors and pharmacists".

Robert Schenk , National Sales Director of AMP, commented, "AMP has been able to assemble a wide range of leading medical cannabis flower and extract brands products for sale during challenging times during the Corona pandemic. Our nationwide sales team has been trained to help educate doctors about the benefits of medical cannabis in patient therapy."

About AMP

AMP Alternative Medical Products Inc. (formerly AMP German Cannabis Group Inc.) is a pharmaceutical narcotic supplier of medical cannabis to German pharmacies with offices in Erfurt and Berlin , Germany.  AMP operates in accordance with the German Narcotic Drug Act (BtMG) and with the Free State of Thuringia, ensuring medical cannabis products imported by AMP from around the world and sold in Germany meets the European Union - Good Manufacturing Practice (EU-GMP) standard. AMP's nationwide sales team represent medical cannabis product brands from Aphria , Bedrocan and Little Green Pharma . Learn more at www.amp-eu.com .

The AMP Roundtable Series discusses issues about medical cannabis in Germany and is available as a podcast and video. In Episode #2, "Politics and Medical Cannabis in Germany " Dr. Wieland Schinnenburg , MdB (FDP), provides an up-to-date overview of the political issues and challenges facing the medical cannabis industry in Germany . Learn more at www.amp-eu.de/roundtable .

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guaranteeing of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

AMP Alternative Medical Products Inc. Logo (CNW Group/AMP Alternative Medical Products)

SOURCE AMP Alternative Medical Products

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/April2021/07/c7286.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration.

For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.gov/edgar.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

-

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Wilkes-Barre, Pennsylvania

New dispensary expands patient access to medical marijuana with ribbon cutting and pop-up event

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing marijuana company in the U.S., today announced the opening of a new Trulieve-affiliated medical marijuana dispensary in Wilkes-Barre, Pennsylvania .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Gulf Breeze, Florida

New Santa Rosa County location will host grand opening celebration Friday, July 12th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Gulf Breeze, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Second Quarter 2024 Results Conference Call on August 6, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, August 6, 2024 at 8:30 AM Eastern Time following the release of its second quarter 2024 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830

Passcode:

1732811

International: 1-412-542-4136

Passcode:

1732811

A live audio webcast of the conference call will be available at:
Trulieve Second Quarter 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-second-quarter-2024-results-conference-call-on-august-6-2024-302191314.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/09/c4702.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Hygrovest Limited

HGV Appendix 4D - Half Year Report

Hygrovest Limited (ASX:HGV) ("HGV")is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium to long term from investments in listed and unlisted equities and other financial assets.

HGV encloses the Appendix 4D and financial statements in respect of the half year ended 31 December 2021 lodged in accordance with ASX LR4.2B.

Keep reading...Show less

Latest Press Releases

Related News

×